The ganciclovir intraocular device (GIOD) is an ingenious delivery system that may control cytomegalovirus (CMV) retinitis. The recent article by Anand et al1 describing the GIOD, however, did not address the issue of patient survival.
The data contained in Figure 1 of the article by Anand et al1 were used to perform Kaplan-Meier product-limit analysis. Only the data from the first eye of each patient listed to receive therapy with the GIOD were used for survival analysis. These data were also stratified into two groups: those patients who received intravenous ganciclovir sometime in the course of their treatment and those patients who did not. These two groups were compared using the log-rank test.
The median survival for the entire group was 134 days. The median survival for those patients who received intravenous ganciclovir was 249 days. The median survival for those patients not treated with intravenous ganciclovir was
Spaide RF. Ganciclovir Intraocular Device and Patient Survival. Arch Ophthalmol. 1994;112(1):19–20. doi:10.1001/archopht.1994.01090130029004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: